Sanofi upgraded to “overweight” by J.P. Morgan on late-stage drug prospects

Published 08/08/2025, 09:34
© Reuters.

Investing.com -- J.P. Morgan has upgraded Sanofi’s (EPA:SASY) rating to “overweight” from “neutral,” setting a December 2026 price target of €105, down from the previous €110, in a note dated Friday. 

The brokerage cited a favorable outlook for two late-stage drugs, amlitelimab for atopic dermatitis and tolebrutinib for primary progressive multiple sclerosis, as key factors behind the change.

Amlitelimab’s Phase III COAST-1 trial results, expected in the third quarter of 2025, are projected to show 28% to 34% placebo-adjusted EASI-75 efficacy at week 24 for a four-week dosing schedule, similar to competing drugs but with less frequent dosing. 

J.P. Morgan estimates the drug could generate €2 billion to €3 billion in peak sales, with further potential if a 12-week maintenance schedule performs well in a separate 2026 trial.

Tolebrutinib’s Phase III PERSEUS trial in primary progressive multiple sclerosis is due in the third or fourth quarter of 2025. 

Prior data from other multiple sclerosis forms suggest the drug could achieve statistically significant reductions in confirmed disability progression, potentially supporting at least €1 billion in sales in this indication alone. 

Across primary and secondary progressive forms, J.P. Morgan forecasts unadjusted peak sales of €2.9 billion.

The brokerage’s revised forecasts reflect 2% to 3% cuts to 2025-2030 sales and business EPS due to currency headwinds, but its 2026 business EPS growth projection remains 11% on an underlying basis. 

Sanofi’s shares are trading at a 20% discount to the sector despite a 2025-2030 EPS compound annual growth rate of 7%, which J.P. Morgan says is 50% above the sector average.

The price target is based on a sum-of-the-parts valuation applying roughly 12 times 2026 estimated earnings per share and including Sanofi’s 47.8% stake in Opella, valued at €3 per share.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.